Targeted chemotherapy for breast cancer: Patients perception of the use of tumor gene profiling approaches to better adapt treatments;Chimiothérapie ciblée du cancer du sein basée sur une analyse génomique de la tumeur: Adhésion des patientes, craintes et malentendus

Medecine/Sciences

Volumn 28, Issue SPEC. ISSUE 1, 2012, Pages 24-27

  Pellegrini, Isabelle ^a,b   Rapti, Myrto ^a,b   Extra, Jean Marc ^c   Petri Call, Anouk ^b   Apostolidis, Themis ^a,b   Ferrero, Jean Marc ^e   Bachelot, Thomas ^f   Viens, Patrice ^c,d   Bertucci, François ^c,d   Julian Reynier, Claire ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; CARCINOMA; COMMUNICATION DISORDER; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METHODOLOGY; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PERCEPTION; PERSONALIZED MEDICINE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; UTILIZATION REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; COMMUNICATION BARRIERS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; PERCEPTION;

EID: 84860849494     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/201228s107     Document Type: Review

References (24)

1. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005 ; 365 : 1687-717.
2. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009 ; 360 : 790-800.
3. Bertucci F, Nasser V, Granjeaud S, et al. Gene expression profiles of poorprognosis primary breast cancer correlate with survival. Hum Mol Genet 2002 ; 11 : 863-72. (Pubitemid 34449774)
4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006 ; 295 : 2492-502. (Pubitemid 43854964)
5. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003 ; 362 : 362-9. (Pubitemid 36957839)
6. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 ; 24 : 4236-44. (Pubitemid 46630780)
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-52.
8. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530-6. (Pubitemid 34130608)
9. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009. (Pubitemid 35461656)
10. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010 ; 120 : 655-61.
11. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006 ; 24 : 3726-34. (Pubitemid 46622311)
12. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: A prospective community-based feasibility study (RASTER). Lancet Oncol 2007 ; 8 : 1079-87. (Pubitemid 350182954)
13. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol, 2010 ; 28 : 1671-6.
14. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007 ; 3 : 182-6. (Pubitemid 351593669)
15. Retel VP, Bueno-de-Mesquita JM, Hummel MJ, et al. Constructive technology assessment (CTA) as a tool in coverage with evidence development: The case of the 70-gene prognosis signature for breast cancer diagnostics. Int J Technol Assess Health Care 2009 ; 25 : 73-83.
16. Sparano JA, Solin LJ. Defining the clinical utility of gene expression assays in breast cancer: The intersection of science and art in clinical decision making. J Clin Oncol 2010 ; 28 : 1625-7.
17. Nielsen LF, Moldrup C. Lay perspective on pharmacogenomics: A litterature review. Personalized Medicine 2006 ; 3 : 311-6.
18. O'Neill SC, Brewer NT, Lillie SE, et al. Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol 2007 ; 25 : 4628-34. (Pubitemid 350035323)
19. Richman AR, Tzeng JP, Carey LA, et al. Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 2011 ; 20 : 28-35.
20. Tzeng JP, Mayer D, Richman AR, et al. Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 2010 ; 116 : 1992-2000.
21. Pellegrini I, Rapti M, Extra JM, et al. Tailored chemotherapy based on tumor gene expression analysis: Breast cancer patients misinterpretations and positive attitudes. Eur J Cancer Care 2012 (sous presse).
22. Moldrup C. Ethical, social and legal implications of pharmacogenomics: A critical review. Community Genet 2001 ; 4 : 204-14. (Pubitemid 34762158)
23. Turnquist DC, Harvey JH, Andersen BL. Attributions and adjustment to life-threatening illness. Br J Clin Psychol 1988 ; 27 : 55-65. (Pubitemid 18055578)
24. Thorne S, Oliffe J, Kim-Sing C, et al. Helpful communications during the diagnostic period: An interpretive description of patient preferences. Eur J Cancer Care (Engl) 2010 ; 19 : 746-54.